Novo Nordisk loses big U.S. contracts; Victoza, NovoLog sales to suffer

Novo Nordisk's ($NVO) diabetes drugs have been revving up sales in the U.S. But the Danish drugmaker has lost two big supply contracts, and that's likely to put a drag on growth.

In farming out new supply contracts for 2014, pharmacy benefits manager Express Scripts shut out Novo's fast-growing Victoza and top-selling modern insulin NovoLog (sold as NovoRapid in the U.S.). Express Scripts chose to use Eli Lilly's ($LLY) insulin instead of NovoRapid, and Bristol-Myers Squibb ($BMY) and AstraZeneca's ($AZN) Byetta and Bydureon.

Express Scripts controls a big share of the U.S. drug market. As Reuters notes, the PBM's prescription programs cover between 40 million and 45 million people in the U.S., and a DNB Markets analyst estimates that the PBM's business accounted for 15-20% of Victoza's U.S. sales.

Sydbank analyst Søren Løntoft Hansen figures Novo could lose 1-2 percentage points off its market share because of the move. "This is a serious blow for Novo Nordisk," Hansen said (as quoted by Reuters). "I think it will hit earnings per share by closer to 3% in 2014."

Jyske Bank was a bit more sanguine, expecting the contract loss to ding sales by about 1% and operating profits by 1.8%.

Hansen said he was most surprised by Express Scripts' choice to replace Victoza. The drug has been growing at a fantastic rate, with first-half sales up 32% to 5.55 billion kroner, or about $980 million. That's on top of a whopping 58% increase in 2012, to 9.5 billion kroner. Hansen said he expects the drug to keep on a growth track next year, but at not quite the same rate.

- read the Reuters news

Special Reports: Top 10 Diabetes Drugs

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…